Prothena Co. PLC Company Profile (NASDAQ:PRTA)

About Prothena Co. PLC (NASDAQ:PRTA)

Prothena Co. PLC logoProthena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004). The Company has generated monoclonal antibodies that selectively bind to amyloidogenic (diseased) forms of the Transthyretin (TTR)-mediated amyloidosis (ATTR) protein. The Company's pipeline also includes late discovery-stage programs for which the Company is testing the efficacy of antibodies in preclinical models of diseases related to amyloid or cell adhesion.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:PRTA
  • CUSIP: N/A
  • Web:
  • Market Cap: $2.09 billion
  • Outstanding Shares: 38,020,000
Average Prices:
  • 50 Day Moving Avg: $53.17
  • 200 Day Moving Avg: $53.71
  • 52 Week Range: $33.53 - $68.18
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -11.13
  • P/E Growth: 0.69
Sales & Book Value:
  • Annual Revenue: $1.05 million
  • Price / Sales: 1,986.09
  • Book Value: $13.07 per share
  • Price / Book: 4.20
  • EBIDTA: ($157,960,000.00)
  • Net Margins: -11,365.41%
  • Return on Equity: -32.65%
  • Return on Assets: -29.13%
  • Current Ratio: 11.26%
  • Quick Ratio: 11.26%
  • Average Volume: 304,981 shs.
  • Beta: 2.52
  • Short Ratio: 16.79

Frequently Asked Questions for Prothena Co. PLC (NASDAQ:PRTA)

What is Prothena Co. PLC's stock symbol?

Prothena Co. PLC trades on the NASDAQ under the ticker symbol "PRTA."

How were Prothena Co. PLC's earnings last quarter?

Prothena Co. PLC (NASDAQ:PRTA) issued its quarterly earnings results on Tuesday, May, 9th. The company reported ($0.99) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($1.32) by $0.33. The firm earned $0.26 million during the quarter, compared to the consensus estimate of $0.26 million. Prothena Co. PLC had a negative return on equity of 32.65% and a negative net margin of 11,365.41%. The company's revenue for the quarter was down 3.7% on a year-over-year basis. During the same quarter last year, the company posted ($0.81) EPS. View Prothena Co. PLC's Earnings History.

Where is Prothena Co. PLC's stock going? Where will Prothena Co. PLC's stock price be in 2017?

12 brokers have issued twelve-month price targets for Prothena Co. PLC's stock. Their predictions range from $65.00 to $95.00. On average, they expect Prothena Co. PLC's stock price to reach $77.00 in the next year. View Analyst Ratings for Prothena Co. PLC.

What are analysts saying about Prothena Co. PLC stock?

Here are some recent quotes from research analysts about Prothena Co. PLC stock:

  • 1. According to Zacks Investment Research, "The narrower-than-expected loss in the first quarter was encouraging. Prothena’s efforts on developing its pipeline are encouraging. The company's elicense agreement with Roche for the development and commercialization of selected antibodies targeting alpha-synuclein is a big positive. The collaboration not only boosts Prothena’s pipeline development but also provides it with funds in the form of research reimbursement and milestone payments.The company’s shares have outperformed the Medical/Biomedical Genetics industry in the past one year. However, Prothena is highly dependent on its collaboration partners for the development of its candidates. The company itself does not have enough resources to independently conduct studies on its candidates." (5/15/2017)
  • 2. Cantor Fitzgerald analysts commented, "Sticking to their knitting. In prior experience, PRTA scientists developed monoclonal antibodies (MAbs) bapineuzumab and natalizumab (Tysabri) that targeted misfolded protein (beta amyloid) and prevented T cell trafficking, respectively." (4/12/2017)
  • 3. Instinet analysts commented, "We are initiating on Prothena Corporation (PRTA) with a Buy rating and an $87 target price. We recommend owning PRTA shares ahead of Phase 2b PRONTO trial readout expected in early 2018 for lead asset NEOD001 in AL amyloidosis (a >$1.5bn peak sales opportunity). We view the pullback from 2016 highs and recent lows as an opportunity to accumulate the shares ahead of PRONTO data. Positive results from PRONTO based on change in NT-proBNP, a biomarker that NEOD001 substantially moved, yielding 53% responder rate in an early Phase 1/2b, are likely to support a conditional approval in the EU by 2019. In addition, we expect biomarker data from the PRX003 Phase 1b study to define mechanistically the breadth opportunity for MCAM/Th17-cell targeting in autoimmune disease, a potential multibillion dollar opportunity that, in our view, will raise the floor on PRTA's valuation. PRX002 could become a strong driver of PRTA's valuation in out years; however, given few near-term catalysts, it is unlikely to be a driver for PRTA shares in the next 12 months." (3/1/2017)

Who are some of Prothena Co. PLC's key competitors?

Who owns Prothena Co. PLC stock?

Prothena Co. PLC's stock is owned by a number of of retail and institutional investors. Top institutional investors include Woodford Investment Management Ltd (31.71%), FMR LLC (16.16%), Wellington Management Group LLP (9.02%), BlackRock Inc. (7.80%), State Street Corp (3.05%) and Palo Alto Investors LLC (3.01%). Company insiders that own Prothena Co. PLC stock include Arthur W Homan, Christopher S Henney, Dale B Schenk, Dennis J Selkoe, Gene G Kinney, Karin L Walker, Lars Ekman, Martin Koller, Tara Nickerson and Tran Nguyen. View Institutional Ownership Trends for Prothena Co. PLC.

Who sold Prothena Co. PLC stock? Who is selling Prothena Co. PLC stock?

Prothena Co. PLC's stock was sold by a variety of institutional investors in the last quarter, including Westfield Capital Management Co. LP, Morgan Stanley, Wells Fargo & Company MN, UBS Group AG, Pinnacle Associates Ltd., State Street Corp, American Century Companies Inc. and Turner Investments LLC. Company insiders that have sold Prothena Co. PLC stock in the last year include Arthur W Homan, Dennis J Selkoe, Gene G Kinney and Karin L Walker. View Insider Buying and Selling for Prothena Co. PLC.

Who bought Prothena Co. PLC stock? Who is buying Prothena Co. PLC stock?

Prothena Co. PLC's stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Woodford Investment Management Ltd, FMR LLC, Redmile Group LLC, Wellington Management Group LLP, Loomis Sayles & Co. L P, Vanguard Group Inc. and Palo Alto Investors LLC. View Insider Buying and Selling for Prothena Co. PLC.

How do I buy Prothena Co. PLC stock?

Shares of Prothena Co. PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Prothena Co. PLC stock cost?

One share of Prothena Co. PLC stock can currently be purchased for approximately $54.85.

Analyst Ratings

Consensus Ratings for Prothena Co. PLC (NASDAQ:PRTA) (?)
Ratings Breakdown: 12 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $77.00 (40.38% upside)

Analysts' Ratings History for Prothena Co. PLC (NASDAQ:PRTA)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/19/2017BTIG ResearchInitiated CoverageBuy$80.00HighView Rating Details
5/16/2017Piper Jaffray CompaniesReiterated RatingBuyMediumView Rating Details
5/11/2017Oppenheimer Holdings Inc.Set Price TargetBuy$70.00LowView Rating Details
4/12/2017Cantor FitzgeraldInitiated CoverageOverweight$86.00HighView Rating Details
4/3/2017WedbushReiterated RatingOutperform$77.00HighView Rating Details
3/1/2017InstinetInitiated CoverageBuy -> Buy$87.00N/AView Rating Details
3/1/2017NomuraInitiated CoverageBuyN/AView Rating Details
12/20/2016SunTrust Banks, Inc.Initiated CoverageBuy$75.00N/AView Rating Details
11/3/2016Deutsche Bank AGInitiated CoverageBuy$73.00N/AView Rating Details
9/27/2016Credit Suisse Group AGReiterated RatingBuy$65.00N/AView Rating Details
8/4/2016Barclays PLCBoost Price TargetOverweight$60.00 -> $70.00N/AView Rating Details
7/18/2016Royal Bank of CanadaReiterated RatingOutperform$95.00N/AView Rating Details
6/19/2015Ladenburg Thalmann Financial ServicesBoost Price TargetBuy$49.00 -> $57.00N/AView Rating Details
(Data available from 5/26/2015 forward)


Earnings History for Prothena Co. PLC (NASDAQ:PRTA)
Earnings by Quarter for Prothena Co. PLC (NASDAQ:PRTA)
Earnings History by Quarter for Prothena Co. PLC (NASDAQ:PRTA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/20173/31/2017($1.32)($0.99)$0.26 million$0.26 millionViewN/AView Earnings Details
2/14/2017Q416($1.12)($1.41)$5.35 million$0.20 millionViewListenView Earnings Details
11/1/2016Q3($1.22)($1.26)$0.49 million$0.29 millionViewN/AView Earnings Details
8/2/2016Q2($0.91)($1.18)$0.39 million$0.33 millionViewN/AView Earnings Details
5/3/2016Q116($0.77)($0.81)$0.27 million$0.27 millionViewN/AView Earnings Details
2/18/2016Q215($0.81)($0.76)$0.39 million$0.31 millionViewListenView Earnings Details
11/2/2015($0.66)($0.73)$0.28 million$0.43 millionViewN/AView Earnings Details
8/4/2015Q2($0.56)($0.59)$0.60 million$0.28 millionViewN/AView Earnings Details
5/5/2015($0.59)($0.55)$1.95 million$0.59 millionViewN/AView Earnings Details
3/5/2015Q414($0.66)($0.48)$1.20 million$2.00 millionViewN/AView Earnings Details
11/3/2014Q314($0.60)($0.48)$1.13 million$1.50 millionViewN/AView Earnings Details
8/4/2014Q214$0.06$15.17 million$15.12 millionViewN/AView Earnings Details
5/5/2014$0.81$0.78$30.17 million$32.23 millionViewN/AView Earnings Details
3/6/2014Q113($0.52)ViewN/AView Earnings Details
3/28/2013Q412($0.82)$0.13 million$0.58 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Prothena Co. PLC (NASDAQ:PRTA)
2017 EPS Consensus Estimate: ($5.07)
2018 EPS Consensus Estimate: ($5.00)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($1.42)($1.28)($1.36)
Q2 20173($1.20)($0.50)($0.94)
Q3 20173($1.62)($0.74)($1.23)
Q4 20173($1.96)($1.26)($1.54)
Q1 20181($1.39)($1.39)($1.39)
Q2 20181($1.36)($1.36)($1.36)
Q3 20181($1.18)($1.18)($1.18)
Q4 20181($1.07)($1.07)($1.07)
(Data provided by Zacks Investment Research)


Dividend History for Prothena Co. PLC (NASDAQ:PRTA)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Prothena Co. PLC (NASDAQ:PRTA)
Insider Ownership Percentage: 3.70%
Insider Trades by Quarter for Prothena Co. PLC (NASDAQ:PRTA)
Institutional Ownership by Quarter for Prothena Co. PLC (NASDAQ:PRTA)
Insider Trades by Quarter for Prothena Co. PLC (NASDAQ:PRTA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/17/2017Karin L WalkerInsiderSell5,000$52.25$261,250.00View SEC Filing  
4/3/2017Dennis J SelkoeDirectorSell3,500$55.86$195,510.00View SEC Filing  
3/9/2017Tran NguyenCFOBuy1,000$51.32$51,320.00View SEC Filing  
1/4/2017Arthur W HomanInsiderSell3,125$52.25$163,281.25View SEC Filing  
11/28/2016Dennis J SelkoeDirectorSell5,000$62.42$312,100.00View SEC Filing  
11/9/2016Gene G KinneyInsiderSell8,548$55.32$472,875.36View SEC Filing  
10/21/2016Gene G KinneyInsiderSell20,619$55.10$1,136,106.90View SEC Filing  
10/13/2016Karin L WalkerInsiderSell5,000$54.23$271,150.00View SEC Filing  
9/19/2016Karin L WalkerInsiderSell12,000$61.10$733,200.00View SEC Filing  
9/1/2016Arthur W HomanInsiderSell3,125$52.16$163,000.00View SEC Filing  
7/20/2016Arthur W HomanInsiderSell9,375$52.14$488,812.50View SEC Filing  
5/24/2016Dennis J SelkoeDirectorSell5,000$45.00$225,000.00View SEC Filing  
4/13/2016Karin L WalkerInsiderSell4,000$45.11$180,440.00View SEC Filing  
4/4/2016Dennis J SelkoeDirectorSell5,000$45.00$225,000.00View SEC Filing  
1/13/2016Karin L. WalkerinsiderSell4,000$50.96$203,840.00View SEC Filing  
12/9/2015Tara NickersoninsiderSell10,000$66.17$661,700.00View SEC Filing  
12/9/2015Tran NguyenCFOSell30,000$66.17$1,985,100.00View SEC Filing  
12/1/2015Dennis J. SelkoeDirectorSell3,125$68.74$214,812.50View SEC Filing  
11/27/2015Christopher S. HenneyDirectorSell5,000$75.00$375,000.00View SEC Filing  
11/25/2015Lars EkmanDirectorSell30,000$73.35$2,200,500.00View SEC Filing  
11/13/2015Martin KollerinsiderSell30,000$65.03$1,950,900.00View SEC Filing  
11/2/2015Arthur W. HomaninsiderSell3,125$52.14$162,937.50View SEC Filing  
10/29/2015Christopher S. HenneyDirectorSell5,000$55.00$275,000.00View SEC Filing  
9/9/2015Tara NickersoninsiderSell10,000$56.06$560,600.00View SEC Filing  
9/2/2015Martin KollerinsiderSell30,000$55.56$1,666,800.00View SEC Filing  
9/1/2015Dennis J. SelkoeDirectorSell3,125$55.45$173,281.25View SEC Filing  
8/20/2015Dale B. SchenkCEOSell30,000$56.65$1,699,500.00View SEC Filing  
8/12/2015Karin L WalkerInsiderSell7,000$62.06$434,420.00View SEC Filing  
6/9/2015Tara NickersonInsiderSell12,000$44.41$532,920.00View SEC Filing  
3/20/2015Tara NickersonInsiderSell13,000$39.99$519,870.00View SEC Filing  
3/9/2015Dennis J SelkoeDirectorSell3,125$25.56$79,875.00View SEC Filing  
8/12/2014Karin L WalkerInsiderSell2,500$20.74$51,850.00View SEC Filing  
8/7/2014Arthur W HomanInsiderBuy2,000$19.12$38,240.00View SEC Filing  
6/6/2014Karin L WalkerInsiderSell8,000$21.58$172,640.00View SEC Filing  
5/12/2014Dale SchenkCEOBuy8,000$20.79$166,320.00View SEC Filing  
5/12/2014Tara NickersonInsiderBuy1,656$21.00$34,776.00View SEC Filing  
5/9/2014Gene KinneyInsiderBuy2,500$19.54$48,850.00View SEC Filing  
5/9/2014Tran NguyenCFOBuy2,200$19.61$43,142.00View SEC Filing  
2/3/2014Co Plc Perrigomajor shareholderSell3,182,253$24.96$79,429,034.88View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Prothena Co. PLC (NASDAQ:PRTA)
Latest Headlines for Prothena Co. PLC (NASDAQ:PRTA)
DateHeadline logoProthena Co. PLC (PRTA) Research Coverage Started at BTIG Research - May 19 at 7:42 AM logoProthena Co. PLC (PRTA) Rating Reiterated by Piper Jaffray Companies - May 17 at 7:50 PM logoProthena Announces Appointment of Sarah Noonberg, MD, PhD as ... - Nasdaq - May 17 at 8:26 AM logoETFs with exposure to Prothena Corp. Plc : May 15, 2017 - May 15 at 6:35 PM logoProthena Co. PLC (PRTA) Given Average Recommendation of "Buy" by Brokerages - May 15 at 2:46 PM logoProthena Co. PLC (PRTA) Lowered to "Hold" at Zacks Investment Research - May 15 at 12:22 PM logoProthena Corp. Plc breached its 50 day moving average in a Bullish Manner : PRTA-US : May 15, 2017 - May 15 at 9:48 AM logoEquities Analysts Offer Predictions for Prothena Co. PLC's Q2 2017 Earnings (PRTA) - May 15 at 7:30 AM logoProthena Co. PLC (PRTA) Forecasted to Earn Q2 2017 Earnings of ($1.20) Per Share - May 15 at 7:28 AM logoProthena Co. PLC (PRTA) Given a $70.00 Price Target at Oppenheimer Holdings Inc. - May 13 at 6:58 PM logoProthena Corp. Plc :PRTA-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017 - May 12 at 8:07 PM logoAnalysts Offer Predictions for Prothena Co. PLC's Q2 2017 Earnings (PRTA) - May 12 at 8:35 AM logoProthena EPS of -$0.99 - May 12 at 12:51 AM logoSunTrust Banks Equities Analysts Increase Earnings Estimates for Prothena Co. PLC (PRTA) - May 11 at 3:42 PM logoWedbush Reaffirms Outperform Rating for Prothena Co. PLC (PRTA) - May 11 at 10:10 AM logoProthena Co. PLC (PRTA) Announces Earnings Results - May 10 at 7:40 PM logoProthena Reports First Quarter 2017 Financial Results and Provides R&D Update - May 9 at 6:53 PM logoProthena reports 1Q loss - May 9 at 6:53 PM logoProthena Corp. Plc breached its 50 day moving average in a Bearish Manner : PRTA-US : May 4, 2017 - May 4 at 7:32 PM logoProthena Co. PLC (PRTA) Earning Somewhat Negative Press Coverage, Study Finds - May 2 at 5:26 PM logoProthena Co. PLC (PRTA) Expected to Announce Earnings of -$1.32 Per Share - May 1 at 9:00 PM logoProthena Co. PLC (PRTA) Set to Announce Quarterly Earnings on Monday - April 29 at 8:36 AM logoProthena Co. PLC (PRTA) Receiving Somewhat Critical Press Coverage, Study Finds - April 28 at 2:50 PM logoProthena to Participate in the Deutsche Bank 42nd Annual Health Care Conference - April 26 at 5:58 PM logoWhat to Expect from Prothena (PRTA) This Earnings Season? - April 26 at 5:58 PM logoProthena Co. PLC (PRTA) Cut to Hold at Zacks Investment Research - April 26 at 2:46 PM logoProthena Co. PLC (PRTA) Earning Somewhat Positive Press Coverage, Study Shows - April 25 at 7:49 PM logoProthena Corp. Plc – Value Analysis (NASDAQ:PRTA) : April 24, 2017 - April 24 at 6:12 PM logoProthena Co. PLC (PRTA) Earning Somewhat Favorable Media Coverage, Study Shows - April 22 at 11:59 AM logoProthena Corp. Plc breached its 50 day moving average in a Bullish Manner : PRTA-US : April 21, 2017 - April 21 at 7:09 PM logoKarin L. Walker Sells 5,000 Shares of Prothena Co. PLC (PRTA) Stock - April 19 at 8:23 PM logoFavorable News Coverage Very Unlikely to Affect Prothena Co. PLC (PRTA) Stock Price - April 19 at 11:51 AM logoProthena Co. PLC (PRTA) Upgraded to "Buy" by Zacks Investment Research - April 18 at 1:32 PM logoPiper Jaffray Companies Begins Coverage on Prothena Co. PLC (PRTA) - April 18 at 8:09 AM logoProthena Co. PLC (PRTA) Earning Somewhat Critical Media Coverage, Report Finds - April 16 at 2:35 PM logoProthena Co. PLC (PRTA) Now Covered by Piper Jaffray Companies - April 13 at 11:14 PM logoProthena Co. PLC (PRTA) Given Media Impact Rating of 0.24 - April 13 at 7:47 PM logoProthena Co. PLC (PRTA) Sees Significant Decline in Short Interest - April 12 at 6:20 PM logoProthena Co. PLC (PRTA) Research Coverage Started at Cantor Fitzgerald - April 12 at 4:36 PM logo Analysts Expect Prothena Co. PLC (PRTA) Will Announce Earnings of -$1.31 Per Share - April 10 at 2:28 PM logoOppenheimer Holdings Inc. Analysts Give Prothena Co. PLC (PRTA) a $70.00 Price Target - April 7 at 8:59 PM logoProthena Corp. Plc breached its 50 day moving average in a Bearish Manner : PRTA-US : April 6, 2017 - April 7 at 12:02 PM logoInsider Selling: Prothena Co. PLC (PRTA) Director Sells 3,500 Shares of Stock - April 5 at 8:30 PM logoProthena Co. PLC Forecasted to Post Q1 2017 Earnings of ($1.39) Per Share (PRTA) - April 5 at 11:19 AM logoProthena Co. PLC (PRTA) Forecasted to Post Q1 2018 Earnings of ($1.60) Per Share - April 4 at 1:19 PM logoProthena Co. PLC's (PRTA) "Outperform" Rating Reiterated at Wedbush - April 3 at 2:34 PM logoClinical Results Presented from Prothena’s Phase 1b Study of PRX002/RG7935 Demonstrating Robust Antibody CNS Penetration and Significant Reduction of Free Serum Alpha-synuclein in Patients with Parkinson’s Disease - April 2 at 11:09 AM logoProthena Corporation plc : Press Release - April 2 at 11:09 AM logoClinical Results Presented from Prothena's Phase 1b Study of PRX002/RG7935 Demonstrating Robust Antibody CNS Penetration and Significant Reduction of Free Serum Alpha-synuclein in Patients with Parkinson's Disease - April 2 at 9:16 AM logoProthena Co. PLC (PRTA) Earns "Buy" Rating from Oppenheimer Holdings Inc. - March 28 at 7:59 AM



Prothena Co. PLC (PRTA) Chart for Friday, May, 26, 2017

This page was last updated on 5/26/2017 by Staff